Osiris Therapeutics
"disappeared" important data when the company announced results Monday
from a mid-stage study of its stem cell therapy Prochymal in heart
attack patients.
Naturally, Osiris didn't come out and tell investors that it was
issuing a misleading press release on the Prochymal heart attack study.
Instead, the company claimed the study was a success. That's not true.
Figuring out Osiris' deception wasn't that difficult if you know how to
parse the language of clinical trial results and look at independent
sources of information for the truth.
Ride along with me as I pick apart Osiris' statements regarding the Prochymal heart attack study.
Interpreting clinical trial results with a skeptical eye is a crucial
tool for all biotech investors, so apply these skills universally
whenever a drug or biotech company tries to convince you that its drug
works. Hopefully, you'll find most companies are telling the truth, but
sadly and too often, bullish pronouncements about boffo clinical trial
data are just spin jobs ginned up to plaster over problems and bad data.
The U.S. government must move “quickly and decisively” to avert substantial national security risks stemming from artificial intelligence (AI) which could, in the worst case, cause an “extinction-level threat to the human species,” says a report commissioned by the U.S...
By Nada Hassanein, New Jersey Monitor | 03.14.2024
Aggregated News
The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments available to patients with low incomes — and it could...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.